Can MCM8, FSHB, and FSHR variants influence menopause timing and ovarian hormone response?

Menopause timing, gonadotropin regulation, and ovarian response are polygenic, physiologically dynamic traits. These three variants have measurable associations, but their clinical meaning is an average shift in probability—not an individual forecast.

Clinical and endocrine evidence

• MCM8 rs16991615 has the clearest association with age at natural menopause. Predominantly European-ancestry GWAS linked the A allele to approximately 1.07 years later menopause per allele (P=1.2×10⁻²¹); effects in other populations vary with ancestry and allele frequency.
• FSHB rs10835638 (−211G>T) is associated with altered FSH regulation. In normally cycling women, TT homozygosity was associated with approximately 2.05 IU/L higher serum FSH in one study, although genotype groups overlap substantially. In another cohort, the variant explained about 3.6% of measured FSH variation.
• FSHR rs6166 is associated with modest differences during controlled ovarian stimulation: one meta-analysis found 0.84 more retrieved oocytes for AA versus GG, while another associated the Ser allele with poor response (OR 1.29). Effects differ by ancestry and gonadotropin formulation.

Mechanistic context

• The FSHB T allele directly reduces promoter activity in vitro to about 46–58% of the G allele’s activity. Its association with higher circulating FSH likely reflects compensatory endocrine regulation rather than a simple transcription-to-serum relationship.
• In ovulatory women, T alleles were also associated with higher LH and lower progesterone, supporting broader hypothalamic–pituitary–ovarian axis effects.

Clinical interpretation

• Genetic effects are small relative to overall variation: four menopause-associated variants explained 1.4% of menopause-age variance in one cohort, and a broader risk score explained 4.8%.
• Bottom line: The claim is supported. These variants can shift population-level likelihoods of menopause timing, FSH-related physiology, or stimulation response, but should not be used alone to predict an individual woman’s menopausal age, hormone levels, or FSH dose requirement.